Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Pharmacol Ther. 2023 Jan 9;242:108344. doi: 10.1016/j.pharmthera.2023.108344

Fig. 2.

Fig. 2.

RET inhibitor resistance mechanisms. The RET V804M/L gate-keeper mutations confer resistance to MKIs but are overcome by selective RET inhibitors. Solvent front mutations (e.g., RET G10S/C/R) confer resistance to selective RET inhibitors. Mutations or amplifications of MET or NTRK underlie off-target mechanisms of resistance to selective RET inhibitor therapy. EMT may also play a role in acquisition of RET inhibitor resistance.